Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Point-of-Care Diagnostics, Global Health & Biosensors 2019

David Rawling's Biography



David Rawling, Senior Principal Scientist, Inflammatix, Inc.

Dr. David Rawling is the Director of Assay Research and Development at Inflammatix, Inc., a molecular diagnostics company currently focused on host response-based diagnostics for sepsis and infectious diseases. He received his Ph.D. in Molecular Biophysics and Biochemistry from Yale University, where he focused on host-pathogen interactions and assay development for novel compound discovery. Dr. Rawling completed post-doctoral work at Cepheid, Inc. where he focused on rare mutation detection in circulating tumor cells and interrogating oncogene methylation states for diagnostic applications. Dr. Rawling's research is focused on translating emerging amplification and detection technologies to microfluidic, sample-to-answer platforms.

David Rawling Image

Reading the Immune System for Rapid Diagnosis of Acute Infection and Sepsis

Wednesday, 9 October 2019 at 11:00

Add to Calendar ▼2019-10-09 11:00:002019-10-09 12:00:00Europe/LondonReading the Immune System for Rapid Diagnosis of Acute Infection and SepsisPoint-of-Care Diagnostics, Global Health and Biosensors 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Inflammatix is changing how physicians diagnose and treat acute infections and sepsis by leveraging state-of-the-art bioinformatics, assay chemistry and an exclusive, patent-pending biomarker set.?Our initial focus is on development of host response-based diagnostic tests for detecting acute infections and sepsis.


Add to Calendar ▼2019-10-07 00:00:002019-10-09 00:00:00Europe/LondonPoint-of-Care Diagnostics, Global Health and Biosensors 2019Point-of-Care Diagnostics, Global Health and Biosensors 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com